| Name | Title | Contact Details |
|---|
Herself Health is a primary care practice designed for women 65 and up, offering female-focused, age-conscious services that consider every part of health: physical, emotional, spiritual, sexual, and social. Herself Health provides person-centered, value-based care to women 65+ with a focus on mind, body, and soul. This holistic approach to care delivery aims to improve the quality of life of both the women for whom we care and the clinical team of physicians, nurses, and medical assistants. We realize that health is more than just healthcare and our goal is to help each Herself woman live her best life.
Tech-Pro Medical Systems is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VetnCare is a collective of AAHA accredited animal hospitals located in Northern California that believe the highest standard of veterinary care comes from veterinarian owned hospitals, led by their clinical teams.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Humedica, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Brighton, MA. To find more information about Humedica, Inc., please visit www.humedica.com